Athenex Inc Revenue Growth Rates (ATNX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Athenex Inc   (NASDAQ: ATNX)
 

ATNX's Revenue Growth by Quarter and Year

Athenex Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ATNX Revenue (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
4th Quarter December 8.05
3rd Quarter September 33.53
2nd Quarter June 31.52
1st Quarter March 29.72
FY 102.82

ATNXs Annual Revenue
Athenex Inc 's Revenue in the fiscal year 2022 $ 102.82 millions
Athenex Inc 's Revenue in the fiscal year 2021 $ 120.18 millions
Athenex Inc 's Revenue in the fiscal year 2020 $ 144.39 millions
Athenex Inc 's Revenue in the fiscal year 2019 $ 101.23 millions
Athenex Inc 's Revenue in the fiscal year 2018 $ 89.10 millions




ATNX Revenue fourth quarter 2022 Y/Y Growth Comment
Athenex Inc reported drop in Revenue in the fourth quarter 2022 by -67.72% to $ 8.05 millions, from the same quarter in 2021.
The fall in the fourth quarter 2022 Athenex Inc 's Revenue compares unfavorably to the Company's average Revenue rise of 30.84%.

Looking into fourth quarter 2022 results within Major Pharmaceutical Preparations industry 102 other companies have achieved higher Revenue growth. While Athenex Inc ' s Revenue meltdown of -67.72% ranks overall at the positon no. 2175 in the fourth quarter 2022.


ATNX Revenue ( Y/Y Growth %) 2022
 2021 2020 2019
4th Quarter December -67.72 % 14.35 % -36.53 % 61.54 %
3rd Quarter September 3.81 % -8.96 % 83.26 % 5.05 %
2nd Quarter June 43.8 % -45.43 % 80.95 % 91.88 %
1st Quarter March -27.57 % -12.59 % 85.46 % -33.11 %
FY   -14.45 % -16.77 % 42.65 % -

Financial Statements
Athenex Inc 's fourth quarter 2022 Revenue $ 8.05 millions ATNX's Income Statement
Athenex Inc 's fourth quarter 2021 Revenue $ 24.94 millions Quarterly ATNX's Income Statement


ATNX Revenue (Quarter on Quarter Growth %)

 2022
 2021 2020 2019
4th Quarter December -75.99 % -22.79 % -38.53 % 77.48 %
3rd Quarter September 6.38 % 47.35 % -11.68 % -12.79 %
2nd Quarter June 6.06 % -46.58 % -14.42 % -12.29 %
1st Quarter March 19.17 % 88.12 % 36.61 % 18.99 %
FY (Year on Year)   -14.45 % -16.77 % 42.65 % -


Back to ATNX Growth rate Comparisons >> Back to ATNX Growth rate Comparisons >>


Revenue fourth quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #103
Healthcare Sector #289
Overall #2175

Revenue Y/Y Growth Statistics
High Average Low
102.38 % 30.84 % -33.45 %
(Mar 31 2019)   (Mar 31 2022)
Revenue fourth quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #103
Healthcare Sector #289
Overall #2175
Revenue Y/Y Growth Statistics
High Average Low
102.38 % 30.84 % -33.45 %
(Mar 31 2019)   (Mar 31 2022)

Revenue by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Athenex Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
204.55 % 12.52 % -75.99 %
(Sep 30 2017)  


ATNX's IV. Quarter Q/Q Revenue Comment
In the IV. Quarter 2022 Athenex Inc disclosed fall in Revenue from the third quarter by -75.99% to $ 8.05 millions, from $ 33.53 millions achived in the previous reporting period.

But that's not important problem, as Athenex Inc 's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 274 other companies have achieved higher Revenue quarter on quarter growth. While Athenex Inc 's Revenue growth quarter on quarter, overall rank is 4220.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #275
Healthcare Sector #681
Overall #4220
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #275
Healthcare Sector #681
Overall #4220
Revenue Q/Q Growth Statistics
High Average Low
204.55 % 12.52 % -75.99 %
(Sep 30 2017)  


ATNX's IV. Quarter Q/Q Revenue Comment
In the IV. Quarter 2022 Athenex Inc disclosed fall in Revenue from the third quarter by -75.99% to $ 8.05 millions, from $ 33.53 millions achived in the previous reporting period.

But that's not important problem, as Athenex Inc 's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 274 other companies have achieved higher Revenue quarter on quarter growth. While Athenex Inc 's Revenue growth quarter on quarter, overall rank is 4220.


Athenex Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Sep 30 2022)		 12 Months Ending
(Jun 30 2022)		 12 Months Ending
(Mar 31 2022)		 12 Months Ending
(Dec 31 2021)
Cumulative Revenue 12 Months Ending $ 102.82 $ 119.71 $ 118.47 $ 108.88 $ 120.18
Y / Y Revenue Growth (TTM) -14.44 % 2.27 % -1.46 % -21.38 % -16.77 %
Year on Year Revenue Growth Overall Ranking # 2344 # 1993 # 1794 # 2789 # 2694
Seqeuential Revenue Change (TTM) -14.11 % 1.04 % 8.81 % -9.4 % 2.67 %
Seq. Revenue Growth (TTM) Overall Ranking # 3384 # 1614 # 391 # 3577 # 3547


Cumulative Revenue growth Comment
For the 12 months ended Dec 31 2022 Athenex Inc reported a decline in Revenue by -14.44% year on year, to $103 millions, compare to the 2.27% growth at Sep 30 2022.

In the Healthcare sector 318 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1993 to 2344.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 179
Healthcare Sector # 319
Overall # 2344

Revenue TTM Y/Y Growth Statistics
High Average Low
102.38 %
 30.84 %
-33.45 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 179
Sector # 460
S&P 500 # 3384
Cumulative Revenue growth Comment
For the 12 months ended Dec 31 2022 Athenex Inc reported a decline in Revenue by -14.44% year on year, to $103 millions, compare to the 2.27% growth at Sep 30 2022.

In the Healthcare sector 318 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1993 to 2344.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 179
Healthcare Sector # 319
Overall # 2344

Revenue TTM Y/Y Growth Statistics
High Average Low
102.38 %
30.84 %
-33.45 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 179
Sector # 460
S&P 500 # 3384




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ATNX's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue decline for the quarter ending Dec 31 2022 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2022
Amgen Inc -0.10%$ -0.102 millions
Bausch Health Companies Inc -0.14%$ -0.137 millions
Bio rad Laboratories Inc -0.34%$ -0.339 millions
Nrc Health-0.40%$ -0.402 millions
Asensus Surgical Inc -0.48%$ -0.485 millions
Bausch and Lomb Corp-0.50%$ -0.500 millions
Teleflex Incorporated-0.51%$ -0.514 millions
Elite Pharmaceuticals Inc -0.62%$ -0.619 millions
Meihua International Medical Technologies Co Ltd-0.66%$ -0.665 millions
Ambrx Biopharma Inc -0.71%$ -0.711 millions
Chemed Corporation-0.85%$ -0.851 millions
Vycor Medical Inc -0.90%$ -0.899 millions
Fonar Corporation-0.91%$ -0.911 millions
Davita Inc -0.92%$ -0.920 millions
Syneos Health Inc -0.98%$ -0.984 millions
Reshape Lifesciences Inc-1.02%$ -1.018 millions
Accuray Incorporated-1.30%$ -1.303 millions
Bellicum Pharmaceuticals Inc -1.57%$ -1.575 millions
Pliant Therapeutics Inc -1.70%$ -1.701 millions
Royalty Pharma Plc-1.73%$ -1.729 millions
Precipio inc -1.81%$ -1.807 millions
Integra Lifesciences Holdings Corp-1.85%$ -1.850 millions
Nexgel Inc -1.88%$ -1.876 millions
Novartis Ag-1.98%$ -1.984 millions
Theravance Biopharma inc -1.99%$ -1.987 millions
Orthofix Medical Inc -2.27%$ -2.267 millions
Travere Therapeutics Inc -2.41%$ -2.412 millions
Heska Corporation-2.54%$ -2.542 millions
Sangamo Therapeutics Inc -2.70%$ -2.701 millions
Glaukos Corp-2.75%$ -2.748 millions


About Athenex Inc Revenue Growth Rates (ATNX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Athenex Inc (CIK 1300699).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-23-124426
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Athenex Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.